Neostigmine is a reversible acetylcholinesterase inhibitor used clinically to manage myasthenia gravis, Ogilvie syndrome, and postoperative urinary retention. By increasing cholinergic transmission at… Read more










































Neostigmine is a reversible acetylcholinesterase inhibitor used clinically to manage myasthenia gravis, Ogilvie syndrome, and postoperative urinary retention. By increasing cholinergic transmission at the neuromuscular junction, it functions as a critical therapeutic agent. Laboratories utilize Neostigmine reference standards, which encompass pharmacopeial and non-pharmacopeial impurities, degradation products, and stable isotope-labelled compounds, to support rigorous pharmaceutical analysis. These materials are essential for effective impurity profiling, enabling the detection and quantification of process-related compounds and synthetic intermediates. Furthermore, stable isotope-labelled compounds serve as internal standards in mass spectrometry workflows, facilitating precise method validation and quality control procedures. By ensuring accurate identification and structural characterization of these related substances, analysts can maintain adherence to regulatory requirements and ensure consistent product quality throughout the drug development lifecycle.